普通外文研报
Initiate at OP: Smile Now, Pay Later
研报英文原文证据摘录
Initiate at OP: Smile Now, Pay Later
tration as low as 5-6%. Even modest penetration gains translate EPS $11.37 $12.35
into significant incremental volume for Align.
Valuation
DSOs are accelerating digital adoption. While the North American retail channel
2025A 2026E 2027E
remains challenged, DSOs delivered double-digit 1Q 2026 volume growth across every
P/E 17.6x 16.3x 15.1xregion, demonstrating that large-scale practices are structurally committed to Align's
digital ecosystem. As DSOs continue consolidating the dental industry globally, their EV/EBITDA 10.9x 10.7x 10.2x
share of Align's volume should grow, providing a durable structural tailwind. EV/Revenue 3.1x 3.0x 2.9x
We see Elliott's involvement as a net positive, adding governance discipline QTR. EPS Q1 Q2 Q3 Q4
without disrupting the core thesis. A likely private settlement could accelerate 2025A $2.13 $2.49 $2.61 $3.29
cost optimization and capital return without derailing critical R&D investments in new 2026E $2.58a $2.63 $2.92 $3.25
product launches. The $1 billion buyback program, with ~$800 million remaining, could
2027E $3.03 $3.09 $3.02 $3.15provide meaningful EPS-accretion support and a floor under the shares.
Limited downside from China VBP. With 85%+ of ALGN's China revenue in the private
sector and VBP implementation focused on public hospitals, the bear case overstates
near-term disruption risk.
Valuation is discounted; we see a path to re-rating. Our $209 target price is
supported by a recovering orthodontic market, a structurally underpenetrated global
TAM of 600 million patients, and a multi-year margin expansion story. We see a re-
rating driven by North American retail channel stabilization, early commercial traction Our Thesis
from new products, and a constructive Elliott settlement.
本摘录由系统从所标注的 PDF 证据页直接提取并保留英文原文,不做批量翻译;登录后在阅读器切换中文时才按需翻译。
打开研报阅读器